Agios Pharmaceuticals, Inc. AGIO
Institutional shares held
63.8 Million
2.06M
calls
911K
puts
Total value of holdings
$2.78B
$89.9M
calls
$39.8M
puts
Market Cap
$2.39B
54,818,000
Shares Out.
Institutional ownership
116.33%
# of Institutions
257
We take great care to ensure that the data presented and summarized in this overview for AGIOS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGIO
View all-
Farallon Capital Management LLC San Francisco, CA5.78MShares$252 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$245 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$212 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.71MShares$162 Million3.19% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.76MShares$121 Million1.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.67MShares$117 Million3.46% of portfolio
-
Wellington Management Group LLP Boston, MA2.47MShares$108 Million0.02% of portfolio
-
Commodore Capital LP New York, NY2.34MShares$102 Million5.99% of portfolio
-
State Street Corp Boston, MA2.26MShares$98.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C31.96MShares$85.5 Million0.09% of portfolio
Latest Institutional Activity in AGIO
Top Purchases
Top Sells
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AGIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,600
$43.84 P/Share
|
|
Nov 12
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Nov 11
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,454
-3.82%
|
$105,522
$43.78 P/Share
|
|
Nov 11
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,454
+3.68%
|
$61,350
$25.01 P/Share
|
|
Oct 30
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
200
-0.32%
|
$8,600
$43.81 P/Share
|
|
Oct 30
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.32%
|
$5,000
$25.01 P/Share
|
|
Oct 27
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,302
-5.08%
|
$141,986
$43.92 P/Share
|
|
Oct 27
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,302
+4.83%
|
$82,550
$25.01 P/Share
|
|
Oct 08
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,200
$41.0 P/Share
|
|
Oct 08
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Sep 30
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,000
$40.0 P/Share
|
|
Sep 30
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Sep 26
2025
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,651
-9.73%
|
$131,436
$36.77 P/Share
|
|
Sep 26
2025
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,472
+16.61%
|
-
|
|
Sep 05
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
8,546
-90.78%
|
$307,656
$36.87 P/Share
|
|
Aug 27
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,000
$40.0 P/Share
|
|
Aug 27
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Aug 11
2025
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
|
Aug 11
2025
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
|
Aug 08
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,085
-8.23%
|
$399,060
$36.67 P/Share
|
Last 12 Months Summary
Buy / Acquisition
250K
Shares
From
14
Insiders
| Exercise of conversion of derivative security | 250K shares |
|---|
Sell / Disposition
116K
Shares
From
8
Insiders
| Open market or private sale | 116K shares |
|---|